Author Archives: admin


Regenerating the Body With Stem Cells Hype or Hope? – Labiotech.eu (blog)

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding.

The overall stem cell therapy field has failed today to show a very clear cut clinical benefit, told me Georges Rawadi, VP for Business Development at Celyad. The field now needs some significant success to attract attention.

Even though investors prefer placing their bets on the hot T cell therapies these days, some stem cell technologies such as iPSCs are starting to get traction as big industry players are exploring the territory. Last year, Bayer and Versant threw $225M into the pot to launch BlueRock Therapeutics, a regenerative medicine company that plans to develop iPSC-based therapies. A year before, Fujifilm spent $307M to acquire the iPSC company Cellular Dynamics.

Although a big success story is still lagging behind, recent advances in the field argue that stem cells indeed have the potential to translate into effective therapies for currently intractable diseases. Heres an overview of what biotechs stem cells are up to!

Stem cell treatment is not a new concept hematopoietic stem cells (HSCs) were described as early as the 1960s and bone marrow transplants have been used to treat blood cancer for decades.

The reason that we get excited about stem cell therapies comes from our experience with the hematopoietic stem cells. If you want to see what a mature stem cell therapy is like, you only need to look at bone marrow transplantation explained James Peyer, Managing Partner at Apollo Ventures, who has a Ph.D. in stem cell biology.

According to Peyer, the hematopoietic stem cell field is one of the most active areas in the stem cell world right now, mainly fueled by our advances in the gene editing space. Tools like CRISPR and TALEN allow for the genetic modification of a patients own bone marrow stem cells, which can then be expanded and returned to the patient for the correction of a genetic defect.

Last year, regulators gave green light to one of the first therapies of this kind. Strimvelis, developed by GSK, consists of an ex vivo stem cell gene therapy to treat patients with the very rare type of Severe Combined Immunodeficiency (SCID). Using the patients own cells avoids the risk of graft versus host disease (GvHD), which still affects around 30% of people receiving a bone marrow transplant.

Small wonder that the CRISPR companies, CRISPR Therapeutics, Editas, and Intellia are all active in this field, with preclinical programs in a number hematological diseases.

To date, the most prominent stem cells in the clinic are mesenchymal stem cells (MSCs), which are moving through more than 300 registered clinical trials for a wide array of diseases. These cells are able to form a variety of tissues including bone, cartilage, muscle or fat, and can be readily harvested from patients or donors for use in autologous or allogeneic therapies.

While MSCs have deluded the biotech scene with good safety profiles in clinical trials, their actual regenerative potential remains controversial, and there have been a great number of clinical failures, which many blame on a lack of demonstrated mechanisms of action.

As Peyer explained, The problem here is that, as opposed to other adult stem cells, the MSC has been unclearly defined. We know roughly what it does but we dont fully understand the molecular mechanisms driving these cells. On top of being unclearly defined, the regenerative powers of MSCs have been massively over-claimed in the past.

Another reason for the lack of clinical benefit has also been attributed to the use of undifferentiated MSCs, as Rawadi explained to me. The Belgian biotech Celyad, which has been pioneering cell therapy in the cardiovascular space, is using bone-marrow derived autologous MSCs and differentiates them into cardiomyocyte precursors to produce new heart muscle in patients with heart failure.

Although the company missed its primary endpoint in a phase III trial last year, Celyad has staked out a patient subpopulation that showed significant improvement. Its technology still has the confidence of the FDA, which just handed out a Fast Track designation and Celyad is now planning a refined Phase III trial.

One of Celyads major competitors, Australian Mesoblast, is forging ahead using allogeneic MSCs with Phase III programs in heart failure, chronic low back pain (CLBP) due to disc degeneration, as well as a range of inflammatory conditions including GvHD and rheumatoid arthritis.

Although the ability of MSCs to regenerate tissues remains questionable, the Mesoblasts approach hinges on a body of evidence showing that MSCs can suppress inflammation and mobilize endogenous repair mechanisms through indirect effects on immune cells.

Indeed, the first-ever approved stem cell therapy, Prochymal, also depends on this mechanism. Prochymal was developed by US-based Osiris Therapeutics and in 2012 received Canadian approval to treat acute GvHD. But after Sanofi opted to shelve its partnership with Osiris prior to FDA approval, the biotech sold out its off-the-shelf stem cell platform to Mesoblast in a $100M deal.

In Belgium, companies like TiGenix and Promethera are also banking on the immunomodulatory properties of MSCs. The companies are developing treatments for patients with Crohns disease and liver diseases, respectively.

The ultimate hope for stem cell therapies has been to regenerate damaged or diseased tissues as found in diabetes, heart failure or blindness. Holostem Terapie Avanzate, a spin-off from the University of Modena and Reggio Emilia was the first company to move towards this goal.

Building on 20 long years of research, the biotech has developed Holoclar, the first and only autologous stem cell therapy (apart from bone marrow transplants) to enter the European market. Holoclar is based on limbal stem cells, located in a part of the eye called the limbus, which can be used to restore eyesight in patients that have lost sight due to burn injuries.

Meanwhile, UK-based Reneuron is developing off-the-shelf therapies that aim to restore the cognitive function of patients following a stroke. Backed by no other than Neil Woodford, the company recently raised an impressive 100M to advance its lead therapy to the market.

The biotechs fetal-derived neural stem cell line CTX was able to significantly reduce the disability of post-stroke patients in a Phase II trial and ReNeuron is now planning to push its candidate into pivotal trials.

A major question in the space a decade ago was safety. Today, theres been a lot of trials done that show that safety is not an issue. I think safety is kind of off the table but efficacy is still a question mark. And thats what were trying to deliver now, Olav Helleb, CEO of ReNeuron, told me.

While neural stem cells and other tissue-specific stem cells are able to regenerate the cells of a particular tissue, Embryonic Stem Cells (ESCs) and their engineered counterparts, iPSCs, are capable of making every cell type in the body, a property known as pluripotency. Pluripotent stem cells can also expand indefinitely in culture and their identification unlocked massive expectations for these cells to transform the regenerative medicine field.

Yet, these cells come with significant challenges associated with the safety of the final preparation. Apart from ethical issues surrounding ESCs, today, a lot of companies have been cautious about using these cells for therapy, because undifferentiated pluripotent cells can drive tumor formation, explained Rawadi. Since ESCs can, in principle, form every cell type, they can lead to the formation of teratomas.

A major reason for the fairly slow progress in the field is based on the difficulties of directing a pluripotent cell to exactly the cell type that is needed for cell therapy. We can readily drive the cells from the undifferentiated state to the differentiated state. However, getting those cells to pause anywhere in the middle of this continuum to yield progenitor cells is incredibly challenging, Peyer explained. Another challenge, he says, is to engraft the cells in the right place to enable them to become fully integrated.

Besides initial hurdles, companies like US-based Asterias or ViaCyte are now running the first Phase I/II trials with ESC-derived cells to treat patients with spinal cord injuries and to restore the beta cells in type I diabetes. So far, the eye has been the the dominant organ for many of the first human clinical trials with pluripotent stem cells, where the cells are assessed in diseases such as age-related macular degeneration (AMD) to restore the loss of the retinal epithelium.

Deriving retinal epithelium from pluripotent cells is relatively easy and in fact, researchers in Japan are now running the very first clinical trial using donor-derived iPSCs to treat patients with AMD. For reasons of safety and standardization, the trial is based on an allogeneic approach. However, since this doesnt offer an exact genetic match, allogeneic therapies raise the prospect of immune rejection, an issue that has been plaguing the use of ESCs.

But the scientists in Japan have contended that iPSC banks could potentially solve this problem. The team in Japan is currently establishing an iPSC bank, consisting of HLA-characterized cell lines from 5-10 different donors, which should match 3050% of Japans population.

Such haplobanks have the benefits of allogeneic cell therapy, namely cost-effectiveness and standardization, but you still have matching immune systems, Peyer agrees.

For now, this remains a vision for the future, but the potential seems enormous. As Julian Howell, CMO of ReNeuron, told me, iPSCs have still got an awful long way to go. For the iPSC program running in Japan, they recently acknowledged that it took about $1.5M and 6 months to treat each patient. Its a great idea but its still got some way to go before it reaches the scale that could get into the clinic.

Images via nobeastsofierce,Natali_ Mis,vchal/ Shutterstock

Read the original here:
Regenerating the Body With Stem Cells Hype or Hope? - Labiotech.eu (blog)

Broomfield’s Regenexx in merger with Iowa company – Boulder Daily Camera

Dr. John Schultz gives an injection of bone marrow derived stem cells into the knee of patient Steve Brink from Washington state at the Regenexx offices in Broomfield June 12. (Paul Aiken / Staff Photographer)

_Broomfield's Regenexx, a stem cell treatment network, has completed its merger with Des Moines, Iowa-based Harbor View Medical.

The company corporate headquarters will move to Des Moines as a result, with the company's medical headquarters remaining in Broomfield, according to spokeswoman Caroline Patterson.

Patterson there would be no layoffs in Broomfield as a result of the merger.

Regenexx co-founder, Dr. Christopher Centeno, a pioneer in using stem cells to treat orthopedic injuries, will maintain his role as chief medical officer and Jason Hellickson will become CEO.

Regenexx treatments include injection of a patient's own stem cells and platelet-rich plasma (PRP) to encourage healing of tendons, joints and muscles.

"Most of what we currently call orthopedic surgery will, in the next 10-20 years, be in the dust bin of history," Centano told the Daily Camera last month. "Thirty years from now, cutting people open and drilling holes will be considered barbaric."

Despite advances in research, critics say the safety and effectiveness of these regenerative treatments is largely unregulated and remains poorly understood.

A study by Mayo Clinic, whose results were published last year, noted that patients in a blind study, who had arthritis in both knees, saw benefits from the treatment, but that it wasn't clear why. Just one knee had actually been injected with the stem cells.

The stem cell treatments,have generated controversy among some medical professionals because they cost thousands of dollars and have not been widely studied. Last year the U.S. Food and Drug Administration (FDA) held a series of scientific meetings examining how best to regulate and ensure the safety and efficacy of this approach.

The Mayo Clinic study, overseen by the FDA, concluded that the procedure it sstudied was safe to undergo, but it was not ready to recommend it for "routine arthritis care."

Still the use of stem cell treatments in everything from veterinary clinics to dermatology orthopedic practices is growing. Founded in 2005, Regenexx lists 48 clinics worldwide, including a new facility it opened in Mumbai this month.

Jerd Smith: 303-473-1332, smithj@dailycamera.com or twitter.com/jerd_smith

See original here:
Broomfield's Regenexx in merger with Iowa company - Boulder Daily Camera

Cancer Biological Therapy market is rising with potential rate at CAGR of 4.7 % till 2023 – MENAFN.COM

(MENAFN Editorial) Global Cancer Biological Therapy Market Information; By Phases (Phase I, Phases II and Phases III); by Type (Monoclonal Antibodies, Interferon's, Interleukins, Cancer growth inhibitors, Gene Therapy and Colony-Stimulating Factors); by End-Users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast to 2023 Market Highlights

Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors.

Request a Sample Report @

Amgen Inc.,Bristol-Myers Squibb,Celgene Corporation,ELI Lilly and Company,F. Hoffmann-La Roche AG,EnGeneIC Ltd,Merck & Co., Inc.,Novartis,Pfizer Inc.Segmentation: The global Cancer Biological Therapy market is segmented on the basis of phases. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the type, the market has been segmented as monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy and colony-stimulating factors. Based on the end-users, the market has been segmented as hospitals & clinics, cancer research centers and laboratories.

Report Details @

Global Cancer Biological Therapy solutions providers, manufacturers & suppliersResearch and development (R & D) companiesMarket research and consulting service providersAademic institutes and universities Regional analysis

Table of Content

2 Introduction

2.2 Scope of Study:

2.4 Market Structure

3.1.1 Primary Research:

4 Market

4.2 Drivers

4.2.2 Growing Demand for Advanced Therapies

Browse Related Statistical Reports

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Email:

#Media Contact Company Name: Market Research Future Contact Person: Akash Anand Email: Phone: 1 646 845 9312 Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - City: Pune State: Maharashtra Country: #India Website:

MENAFN1007201700703268ID1095612060

See more here:
Cancer Biological Therapy market is rising with potential rate at CAGR of 4.7 % till 2023 - MENAFN.COM

UW-Madison scientists grow functional artery cells from stem cells – Madison.com

In a step toward one of stem cell sciences chief goals, UW-Madison researchers have grown functional human artery cells that helped lab mice survive heart attacks.

The development, from the lab of stem cell pioneer James Thomson, could help scientists create arteries to use in bypass surgeries for cardiovascular disease, the nations top killer. Several challenges remain, however, and studies in people are years away.

This work provides valuable proof that we can eventually get a reliable source for functional arterial endothelial cells and make arteries that perform and behave like the real thing, Thomson said in a statement.

The research, reported Monday in the journal Proceedings of the National Academy of Sciences, is part of a federally funded effort at UW-Madison to create artery banks for cardiovascular surgery from universally compatible donors.

In a related project, other UW-Madison researchers are testing three-dimensional heart patches of heart muscle cells, grown from stem cells, in pigs. The goal is to replace diseased or damaged heart tissue in humans.

Since Thomson became the first scientist to successfully grow human embryonic stem cells in a lab in 1998, researchers around the world have been coaxing the universal cells into various cell types heart, pancreas, kidney, brain to develop therapies and better understand diseases.

Today, many researchers use cells reprogrammed to their embryonic state from mature cells known as induced pluri- potent stem, or iPS, cells as the raw material. Thomson helped discover iPS cells in 2007.

Many labs can convert embryonic stem cells or iPS cells into specific cell types, but developing specialized cell lines that are pure, functional and robust has been a challenge.

Thomson and his team set out to find a recipe for growing artery cells that would really function like arteries.

The researchers used two new techniques: single-cell RNA sequencing to identify genes highly expressed in cells that initiate artery development, and CRISPR-Cas9 gene editing to evaluate the function of the genes.

They found that five small molecules and growth factors are needed to encourage iPS cells to become functional artery cells. To their surprise, they discovered that insulin, a common growth factor that had been used before in trying to grow artery cells, actually inhibits such growth.

They used their recipe to make artery cells, and tested the cells in mice that had their left coronary arteries tied off to mimic heart attacks. Four weeks later, 83 percent of mice treated with the cells were alive, compared to 33 percent of mice that didnt get the cells.

We can use those cells to further create tissue-engineered arteries for bypass surgeries, said Jue Zhang, a scientist in Thomsons lab at the Morgridge Institute for Research and lead author of the study.

Developing off-the-shelf bypasses for surgery is the goal of an $8 million, seven-year grant UW-Madison received last year from the National Heart, Lung and Blood Institute to create universal artery banks.

The blood vessels of many cardiovascular disease patients arent suitable for use as bypasses, doctors say, and growing bypasses from individual patients stem cells would be timely and expensive. The hope is to use iPS cells from a rare population of genetically compatible donors to grow arteries anyone could use.

UW-Madison scientists, including engineers Tom Turng and Naomi Chesler and pathologist Igor Slukvin at the Wisconsin National Primate Research Center, plan to grow artery cells on scaffolds and test them in monkeys. If successful, the cells would be produced for human studies at the Waisman Biomanufacturing facility on campus.

The heart patches involve another $8.6 million, seven-year National Institutes of Health grant, shared with the University of Alabama-Birmingham and Duke University.

The patches involve three types of heart cells, derived from iPS cells, said Dr. Tim Kamp, a UW-Madison cardiologist and co-director of the universitys Stem Cell and Regenerative Medicine Center.

In studies in pigs, getting the patches to connect and survive when transplanted to pig hearts after heart attacks remains a challenge, Kamp said. Immune tolerance of the human grafts in pigs is another concern, he said.

But if such hurdles can be overcome, tests in humans could follow.

Go here to read the rest:
UW-Madison scientists grow functional artery cells from stem cells - Madison.com

Vatican’s Academy for Life Appoints Eugenicist – Church Militant

VATICAN CITY (ChurchMilitant.com) - The Pontifical Academy for Life (PAL) has added to its scandal by appointing a eugenicist involved in stem-cell research to its corp of 45 ordinary members, along with a pro-abortion philosopher, another pro-abortion eugenicist and a pro-contraception priest, who also supports euthanasia by starvation.

Professor Katarina Le Blanc, professor of stem cell research at the pro-abortion Swedish Karolinska Institute was appointed last month to PAL under Abp. Paglia. Le Blanc carries out her research, using stem cells derived from aborted babies even though the same academy, under the watch of Pope St. John Paul II, condemned such work in 2000.

In condemning the practice of experimenting on embryonic stem cells, PALremarked, "[It] is not hard to see the seriousness and gravity of the ethical problem posed by ... the production and/or use of human embryos."

There are other appointees to PAL with serious moral issues such as Fr. Maurizio Chiodi, who's supposedly a leading Italian moral theologian. He not only rejectsthe Church's ban on the use of artificial birth control but also believes it isn't obligatory to provide food and water to patients. Contrary to Fr. Chiodi's position, PAL stated in 2000 that food and water must always be provided to patients.

Nigel Biggar, one of 45 new ordinary members chosen to serve a five-year term on the Vatican's pro-life academy, believes it's morally acceptable to abort a person before 18 weeks of gestation. During an interview in 2011,Nigel, an Anglican minister and Regius Professor of Moral and Pastoral Theology at the U.K.'s University of Oxford, stated, "I would be inclined to draw the line for abortion at 18 weeks after conception, which is roughly about the earliest time when there is some evidence of brain activity and therefore of consciousness."

In spite of the fact that many of these appointments to the supposedly pro-life institute are manifestly not pro-life, the head of the institute, Abp. Paglia,defends the appointments.

Have a news tip? Submit news to our tip line.

Like our work? Support us with a donation.

Read the original post:
Vatican's Academy for Life Appoints Eugenicist - Church Militant

New NUH study to test stem cells as treatment for liver disease – TODAYonline

SINGAPORE The use of stem cell treatment to repair liver cirrhosis, or hardening of the liver, will be tested in a clinical trial here involving 46 patients and costing S$2.6 million.

The four-year study, which was launched yesterday, came amid a growing waiting list in Singapore for a liver transplant, which is currently the only cure for patients with end-stage liver cirrhosis.

Conducted by a multi-centre team from several restructured hospitals here, the study is led by the National University Hospital (NUH).

Liver failure is one of the top 20 causes of death in Singapore, but many patients are not suitable for a transplant due to factors such as age and surgical fitness.

Out of every five patients doctors see with end-stage liver disease, only one qualifies for a liver transplant, said Dr Dan Yock Young, principal investigator of the clinical trial and senior consultant at NUHs division of gastroenterology and hepatology.

(A liver transplant) is curative, but it is a complex procedure, and many patients are not suitable for it. For these patients, treatment is limited, but morbidity and mortality rates are high as high as 50 per cent in one year and this is probably worse than many (of the) other terminal illnesses we talk about today, he said.

Animal studies conducted over the last five years have shown that stem cells can reconstruct the micro-environment of a normal liver.

Like how branches are of critical importance in supporting the leaves and fruits of a tree, the endothelial (stem) cells contribute to supporting a nutritious environment for the hepatocyte (liver) cells, Dr Dan explained.

While similar stem-cell studies have been conducted in other centres in Asia, there has been no definitive evidence of the benefits of the treatment for liver patients.

The study will recruit 46 patients aged between 40 and 70 years old, and who are at the terminal stages of chronic liver disease, over three years. It is funded by the National Medical Research Council.

During the clinical trial, patients will be divided into a therapeutic group and a control group.

All patients will receive an injection to stimulate their bone marrow cells as part of the supportive treatment for their liver cirrhosis. However, only patients in the study group will have the stem cells from the bone marrow extracted and deposited directly into their liver for more targeted repair.

Using ones own stem cells will avoid the problem of cell rejection.

The liver tissue will be examined three months later, and an investigation to compare pre- and post-transplant results will be conducted after a year.

Since invasive surgery is not required for stem-cell therapy, the fatality risk is significantly lowered for the patient. However, other risks such as severe bleeding and infections still remain, given the patients weakened condition.

NUH also noted that the stem-cell therapy does not replace liver transplants, and the latter remains the best available treatment for liver cirrhosis.

It is very painful to turn patients away when we cannot offer them a liver transplant, said Dr Dan, adding that this stem cell therapy will serve as an alternative option.

We hope that this is a stepping stone to trials for stem cell candidates, he added.

MORE WAITING FOR A LIVER

The number of people on the waiting list for a liver transplant has been growing in recent years. In June last year, it was reported that there were 54 people on the list, more than double the 24 patients in 2011.

Chronic Hepatitis B remains the primary cause of non-alcoholic fatty liver disease, which refers to a range of liver conditions affecting people who drink little to no alcohol. However, obesity has become a contributing factor to the illness as well.

See the original post here:
New NUH study to test stem cells as treatment for liver disease - TODAYonline

Ashli Stempel helped save her brother’s life. She hopes to inspire others. – GazetteNET

A few small scars on Ashli Stempels lower back are the only evidence that a drill burrowed into her hipbone last year at Brigham and Womens Hospital in Boston. The surgery was to harvest the stem cells in her bone marrow to save her older brother Andrew Stempels life.

At age 27, Andrew was diagnosed with cancer of the white blood cells called Hodgkins lymphoma. Donating her bone marrow so that Andrews body could manufacture healthy blood cells, was a small price to pay to give him a shot at survival, Ashli says.

Since the transplant last August after years of treatment and testing Andrew has been cancer-free and Ashli now volunteers periodically in their hometown of Greenfield, where she serves on the Town Council, to spread awareness about this life-saving treatment.

Our bodies are a cure for some cancers, says Ashli Stempel on a recent Saturday as she handsout sign-up forms atGreenfields Energy Park for the Be A Matchnational donor registry. If even one person joins the registry that is awesome.

Its a sunnyday and Stempel, 30,wearing a black and white spaghetti-strap dress stands behind a booth smiling and talking to passersby.

Everybody wants to cure cancer, but I think not everybody understands that we, ourselves, can be the cure for some types of cancers, she says. I can say that I killed cancer and I am pretty excited about that.

In the hollow spaces in a bodys bones, stem cells inside the bone marrow tissue work to create red blood cells, which feed oxygen to the organs, and make white blood cells to fight infections. The bone marrow also produces blood platelets to help form clots but when a cancer of the blood like, leukemia or lymphoma strikes, these life-supporting systems are thrown out of whack, leaving the bodys immune system unable to fight diseases, infection or the cancer.

Chemotherapy and radiation also can kill off bone marrow tissue, leaving patients with more damage to their immune systems, says physician assistant Susanne Smith, donor services clinician at Dana-Farber/Brigham and Womens Hospitals Cancer Center in Boston.

When transplanted into a cancer patients bloodstream, stem cells, a precursor to all the immune system cells in the body, colonize the bones and help fight any remaining cancer, says Smith.

In many cases (a transplant) is the only cure for a leukemia or lymphoma diagnosis chemotherapy can only get a patient so far, says Mary Halet, director of community engagement at the Be The Match Registry, the Minneapolis organization that manages the largest bone marrow registry in the world. But first, a patient must find a tissue match, that is, a donor who has a similar protein marker called the human leukocyte antigen, which is found on most cells in the body.

There are up to 14,000 patients every year who could benefit from a bone marrow transplant, but many of these people will not receive a donation, says Halet. In most cases, the patient will not finda tissue match in his or her own family andmust seek help from a stranger, she says. A patients likelihood of finding a matching bone marrow donor ranges from 66 percent to 97 percentdepending on ethnic background. White patients have a 97 percent chance of finding a match, while black patients only find a match 66 percent of the time.The difference reflects the complexity of the tissues makeup and the number of donors.

Thats why Halets organization promotes recruitment events like the one Ashli Stempel held in Greenfield.

Stempel says she was ecstatic when she found out that she was a match for her brother. She was in her late 20s at the time, a bubbly woman working in communications at Smith College in Northampton, who grew up in a close-knit family.

Her brother, who was working as a retail manager in the Boston area, had discovered a bump on his collarbone.

I woke up one morning and there was a non-painful lump, Andrew Stempel says.

He ignored it for as long as he could before seeing a doctor who diagnosed it as a swollen lymph node caused by Hodgkins lymphoma.

Cancer is a very scary word. I think what you learn going through it is that it is not such a scary word, you can survive, says Ashli Stempel.

The Stempel family had seen that firsthand years earlier when Andrew and Ashlis mother, Deborah, recovered from breast cancer.

Still, that didnt lessen the anxiety for Andrew. As soon as the doctor said the word cancer, he says, his life started to unravel with a battery of experimental drugs, chemotherapy and radiation.

In the begining there was a lot of uncertainty, he says.

Even through his cancer went into remission after a year, doctors did not expect it to remain that way without high doses of chemo or radiation. The plan was to do a bone marrow transplant for long-term survival.

Still, using donated bone marrow meant taking the risk that Andrews body would reject it, which could be fatal.

So, doctors first wanted to try using Andrews own tissue. That would require removing some of his bone marrow, treating it and then injecting it back into his bloodstream.

Within months of the procedure, however, Andrews cancer returned, indicating to doctors that his body wasnt strong enough to fight it on its own.

Ashli was tested via a mouth swab and Andrew was relieved to learn that she was a tissue match.

I was just overwhelmed with happiness, he says.

Ashli went through a month-long screening process to ensure that she was healthy enough to be a donor. People who have infectious diseases like HIV or hepatitis cannot be donors, nor can those with immune systems weakened by autoimmune diseases. Doctors also prefer to use bone marrow from young donors under the age of 44, says Halet. The registry wont accept donors over 60.

When we are young, our immune systems are at their healthiest and the older we get the less robust they are, she says.

It took two years from the time Ashli first learned she was a match for her brother for the transplant to take place.

Not long aftershe woke up from the surgery, Ashli saw the bone marrow that had been taken from her, a two-literjug ofmilky, red liquid. It was whisked away to another partof the hospital where it ended up in a drip bag connected to a vein in Andrews arm.

Doctors saw hisred and white blood cell counts go up immediately after the transplant.

My sisters cells were working, he says. It was amazing.

Even though the transplant was a success, Andrew had to stay in the hospital for a month. Chemotherapy had caused sores in his mouth, he lost his ability to taste food along withhis appetiteand he droppednearly 30 pounds.

It was tough, day to day, but progressively got better, he says.

Since he was essentially receiving a new immune system, like a newborn baby he also had to be shielded from germs, says Ashli.

When his wife, Meghan Stempel, came to visit him, she needed to wear a facemask and gloves. Even when he returned home, he had to be careful. Hetook a year off from his job to recover, spending many afternoons resting on the couch watching TV. After spending months working to building hisstrength back up,he says, most of his weakness has subsided.

I feel a thousand times better, he says.

He is now cancer free and is returning to hisjob as a retail managerat Sherwin Williams this week.

Following her operation, Ashli took off a few weeks from her job in communications at Smith College, but was back on her feet within a couple days. Her hips were sore which meant limping around the house for a short time.

I was in pain, of course, she says. But its a quick recovery.

A few weeks ago Ashli decided to signup for the national bone marrow donor registry through Be A Matchto donate for a second time.

Her name will stay in the system for the foreseeable future. A match could come up or it might never.

Maybe I will be called on to do it again, who knows?

To learn more about becoming a bone marrow donor or to sign up for the registry, go tobethematch.org.

Potential donors can fill out an online form and the registry will mail a mouth swab kit, which can be returned by mail.

If called, a potential donor will undergo a series of blood tests which will evaluate the suitabililty and safety of the match. Though doctors say risks are low for donors, possible complications include infection and bleeding.

Once a donor is cleared, the transplant procedure could occur within a few weeks or a few months, depending on a recommendation from the patients doctor.

The bone marrow transplant is an outpatient procedure for the donor.Recovery time is only a few days anddonors are typically back to their normal routine in two to seven days.

Donors are told their commitment means being willing to devote up to 30 hours spread over four to six weeks to attend appointments and give the donation.

All medical costs for the donation procedure are covered by the National Marrow Donor Program, which operates the Be The Match Registry, or by the cancer patients medical insurance.

Sometime travel is required. Most travel expenses are covered by Be The Match.

Read more:
Ashli Stempel helped save her brother's life. She hopes to inspire others. - GazetteNET

Clinical trial for stem-cell therapy to reverse liver cirrhosis – The Straits Times

SINGAPORE - The use of stem cells to reverse liver cirrhosis - or the hardening of the liver - is being explored in a clinical trial.

Conducted by a multi-centre team led by the National University Hospital (NUH), doctors aim to determine if stem cell therapy can improve liver function.

Previously, liver cirrhosis, caused by various diseases such as chronic hepatitis B and non-alcoholic fatty liver disease, was thought to be irreversible.

A liver transplant provides a definitive cure to end-stage cirrhosis.

However, in Singapore, less than 5 per cent of end-stage liver cirrhosis patients receive a liver transplant.

The number of people on the waiting list for a liver transplant has been increasing over the years, according to statistics from the Ministry of Health.

In 2007, there were nine on the waiting list, compared with 57 last year. There are around 50 waiting for a liver transplant this year.

Also, many patients do not fulfil the eligibility criteria to receive a liver transplant due to other health complications or being above the age limit of 70 years.

The $2.6 million study, which was launched on Tuesday (July 11),is funded by the National Medical Research Counciland 46 patients will be recruited for it. It will run for four years and patients will not need to bear the costs of the stem cell treatment.

Stem cells will be taken from a patient's own bone marrow and will be isolated and injected directly into the patient's liver to initiate the repair.

Similar therapy treatments have been conducted overseas in countries such asEgypt and India, although they have not been fully evaluated for efficacy.

Associate Professor Dan Yock Young, a senior consultant in the division of gastroenterology and hepatology at NUH, said: "We are conducting the study in a systematic and scientific mannerto get definitive evidence of the effects of the treatment."

He also notes that the stem cell therapy is not a substitute for a liver transplant. "This treatment is not intended to pull patients off the waiting list, but provide an option for those who are not eligible for a transplant."

Original post:
Clinical trial for stem-cell therapy to reverse liver cirrhosis - The Straits Times

CReM Stem Cell Researcher Is Innovator of the Year – BU Today

Those who know ancient historythe first decade of the 21st centuryrecall that embryonic stem cell research was a combustible issue, with supporters cheering the potential to create new tissues from stem cells and opponents decrying the destruction of human embryos that it required. A breakthrough arrived in 2006, when a Japanese researcher developed induced pluripotent stem cells (iPS), adult cells that behaved like embryonic stem cells and had an amazing ability to develop into muscles, skin, nerves, and almost any other cell type. Two years later, a second breakthrough, this one by Gustavo Mostoslavsky, a School of Medicine associate professor of gastroenterology, produced a tool that made it simpler and more efficient to generate iPS. BU patented his tool, called STEMCCA, and he says that its been adopted by more than 700 laboratories worldwide for making iPS.

That contribution to the field has earned Mostoslavsky this years University Innovator of the Year award. The Technology Developmentoffice presents the award to a faculty member whose research yields inventions or innovations benefiting society. Mostoslavsky will receive the award today at BUs annual Tech, Drugs, and Rock n Roll networking event connecting BU researchers and Boston entrepreneurs.

I was humbly surprised and happy, he says, when Gloria Waters, vice president and associate provost for research, emailed him the news. Sometimes it is easy to lose perspective when we get busy on the many tasks of running a labgrant writing, mentoring, budget, and so forthso I guess it is nice, once in a while, to just stop and enjoy the moment, enjoy what we have done so far, and even better, if on the way we have helped many others succeed.

One way Mostoslavsky has helped others succeedthe way that makes him most proud, he saysis to have cofounded, in 2010, BUs Center for Regenerative Medicine, which he codirects. The center, which pursues stem cell research with an emphasis on lung, blood, and gastrointestinal tract diseases, practices open source biology: sharing its discoveries with scientists around the world for free rather than patenting them. In 2013, CReM moved into its own physical quarters on Albany Street on the Medical Campus.

I am delighted to see Dr. Mostoslavskys colleagues choose him for this award, says Waters. STEMCCA has dramatically improved the efficiency with which new stem cells can be generated to treat disease. His success in patenting a tool that has become industry-standard, at the same time as he and the codirectors of the CReM have become renowned for their open source biology, serves as a model to students and other researchers of how to advance science through sharing, at the same time protecting important intellectual property.

More:
CReM Stem Cell Researcher Is Innovator of the Year - BU Today

New approach may kill tumor cells in the brain – Harvard Gazette

Investigators from Brigham and Womens Hospital (BWH) and the Harvard Stem Cell Institute (HSCI) may have discovered a way to kill tumor cells that have metastasized to the brain.

The team has developed cancer-killing viruses that can deliver stem cells via the carotid artery, and applied them to metastatic tumors in the brains of clinically relevant mouse models. The elimination of metastatic skin cancer cells from the brains of these preclinical models resulted in prolonged survival, the investigators report. The study, published online this week in the journal PNAS, also describes a strategy of combining this therapy with immune checkpoint inhibitors.

Metastatic brain tumors often from lung, breast, or skin cancers are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases. Current therapeutic options for such patients are limited, particularly when there are many metastases, said Khalid Shah, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery, who led the study. Our results are the first to provide insight into ways of targeting multiple brain metastatic deposits with stem-cell-loaded oncolytic viruses that specifically kill dividing tumor cells.

In their search for novel, tumor-specific therapies that could target multiple metastases in the brain without damaging adjacent tissues, the research team first developed different BRAF wild-type and mutant mouse models that more closely mimicked what is seen in patients.

They found that injecting patient-derived, brain-seeking melanoma cells into the carotid arteries of the preclinical models resulted in metastatic tumors forming throughout the brain, mimicking what is seen in advanced melanoma cancer patients. The injected cells express markers that allow them to enter the brain and are labeled with bioluminescent and fluorescent markers to enable tracking by imaging technologies.

To devise a potential new therapy, the investigators engineered a population of bone marrow-derived mesenchymal stem cells loaded with oncolytic herpes simplex virus (oHSV), which specifically kills dividing cancer cells while sparing normal cells.

Previous research by Shah and his colleagues had shown that different stem cell types were naturally attracted to tumors in the brain. After first verifying that stem cells injected to the brain would travel to multiple metastatic sites and not to tumor-free areas in their model, the team injected the oHSV-laden stem cells into the carotid arteries of metastasis-bearing mice. This led to significantly slower tumor growth and increased survival, compared with the models that received unaltered stem cells or control injections.

Shah and his colleagues also developed an immunocompetent melanoma mouse model and explored treatments with both stem cell-loaded oHSV and immune checkpoint blockers such as those that target the PD-1/PD-L1 pathway. They found that PD-L1 immune checkpoint blockade significantly improved the therapeutic efficacy of stem cell-based oncolytic virotherapy in melanoma brain metastasis.

We are currently developing similar animal models of brain metastasis from other cancer types, as well as new oncolytic viruses that have the ability to specifically kill a wide variety of resistant tumor cells, said Shah, who is also a professor at Harvard Medical School and a principal faculty member at the Harvard Stem Cell Institute. We are hopeful that our findings will overcome problems associated with current clinical procedures. This work will have direct implications for designing clinical trials using oncolytic viruses for metastatic tumors in the brain.

The study was supported by a Department of Defense Idea Award and a grant from the National Institutes of Health.

Read more:
New approach may kill tumor cells in the brain - Harvard Gazette